Fangzhou Inc.

方舟云康控股有限公司

06086.HK

Operates an online chronic disease management platform in China, providing teleconsultations, e-prescriptions and online retail pharmacy services to patients with hypertension, cardiovascular and respiratory diseases. Largest such platform by average MAU in 2023, per CIC.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Overlapping customers and suppliers
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Seasonality and cyclicality
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances
• Contractual arrangements (VIE)